Dividends & Buybacks ·
POMDOCTOR Limited filed a proxy statement for an extraordinary general meeting on September 30, 2026, seeking…
POMPOMDOCTOR Ltd
POMDOCTOR Limited filed a proxy statement for an extraordinary general meeting on September 30, 2026, seeking shareholder approval to terminate its American Depositary Receipt (ADR) program and directly list Class A ordinary shares on Nasdaq. The filing also proposes a 10-to-1 share consolidation, reducing the number of issued shares from approximately 500 million to 50 million while increasing par value from US$0.0001 to US$0.001. These changes are scheduled to take effect simultaneously with the ADR termination and direct listing. The company operates in the health technology sector, providing digital healthcare services.